Conversely, Kumar et al. 13 found that GATA2 was essential for survival of KRAS mutant NSCLC and the inhibition of GATA2 regulated pathways can play an inhibitory effect on tumor, while nanoparticles carrying siGATA2 lent significant therapeutic promise in KRAS mutant NSCLC therapy. Here, KRAS is linked to neoplasm.